In clinical trials patients receiving Recombinant G-CSF following nonmyeloablative cytotoxic chemotherapy, most adverse experiences are the sequelae of the underlying malignancy or cytotoxic chemotherapy. Medullary bone pain is the only consistently observed adverse reaction attributed to Recombinant G-CSF therapy. This bone pain is generally reported to be of mild-to-moderate severity, and can be controlled in most patients with non-narcotic analgesics.
Other side effects include nausea/vomiting, skeletal pain, alopecia, diarrhea, neutropenic fever, mucositis, fever, fatigue, anorexia, dyspnea, headache, cough, skin rash, chest pain, generalized weakness, sore throat stomatitis, constipation, pain (unspecified).
Spontaneously reversible elevations in uric acid, lactate dehydrogenase, and alkaline phosphatase is seen in patients receiving Recombinant GCSF therapy following cytotoxic chemotherapy; increases were generally mild-to-moderate. There are no serious, life-threatening, or fatal adverse reactions attributed to Recombinant G-CSF therapy.